A cancer drug just found a brand-new way to switch off a tumor's engine

For people facing hard-to-treat cancers, hope just got more specific. Scientists in Geneva and Frankfurt have worked out exactly how an experimental drug called roginolisib works: it locks a cancer-driving enzyme into its 'off' position — a trick no earlier drug in its class could manage. In a first study in 44 patients, the drug was well tolerated, and people with a rare eye cancer lived a median of 20.8 months, roughly triple what past treatments achieved. The discovery, described in two new papers in Nature Communications, now heads into larger trials.